Oxford Immunotec Global PLC (NASDAQ:OXFD) Director Richard A. Sandberg sold 3,000 shares of the stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $19.90, for a total value of $59,700.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
NASDAQ OXFD traded down $0.37 on Monday, reaching $12.84. The company had a trading volume of 189,773 shares, compared to its average volume of 179,073. The stock has a market capitalization of $351.69 million, a PE ratio of 25.18 and a beta of 0.33. The business has a fifty day moving average price of $13.49. Oxford Immunotec Global PLC has a 52-week low of $11.88 and a 52-week high of $19.19. The company has a quick ratio of 12.03, a current ratio of 12.60 and a debt-to-equity ratio of 0.04.
Oxford Immunotec Global (NASDAQ:OXFD) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.14. The business had revenue of $14.79 million during the quarter, compared to analyst estimates of $13.74 million. Oxford Immunotec Global had a return on equity of 13.56% and a net margin of 172.27%. Oxford Immunotec Global’s quarterly revenue was up 26.6% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.40) EPS. Sell-side analysts predict that Oxford Immunotec Global PLC will post -0.24 earnings per share for the current fiscal year.
OXFD has been the subject of a number of analyst reports. ValuEngine lowered Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research report on Tuesday, July 23rd. Zacks Investment Research lowered Oxford Immunotec Global from a “buy” rating to a “hold” rating in a research report on Thursday. BidaskClub raised Oxford Immunotec Global from a “strong sell” rating to a “sell” rating in a research report on Saturday. Finally, TheStreet lowered Oxford Immunotec Global from a “c-” rating to a “d+” rating in a research report on Monday, July 15th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and one has given a buy rating to the company. Oxford Immunotec Global currently has a consensus rating of “Hold” and a consensus price target of $18.00.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Northern Trust Corp boosted its stake in shares of Oxford Immunotec Global by 0.7% in the 4th quarter. Northern Trust Corp now owns 290,723 shares of the company’s stock valued at $3,715,000 after purchasing an additional 2,113 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Oxford Immunotec Global by 15.9% in the 4th quarter. Geode Capital Management LLC now owns 101,930 shares of the company’s stock valued at $1,302,000 after purchasing an additional 13,974 shares during the last quarter. Squarepoint Ops LLC boosted its stake in shares of Oxford Immunotec Global by 36.1% in the 4th quarter. Squarepoint Ops LLC now owns 19,303 shares of the company’s stock valued at $247,000 after purchasing an additional 5,120 shares during the last quarter. Millennium Management LLC boosted its stake in shares of Oxford Immunotec Global by 117.2% in the 4th quarter. Millennium Management LLC now owns 117,914 shares of the company’s stock valued at $1,507,000 after purchasing an additional 63,617 shares during the last quarter. Finally, BNP Paribas Arbitrage SA boosted its stake in shares of Oxford Immunotec Global by 59,988.9% in the 1st quarter. BNP Paribas Arbitrage SA now owns 5,408 shares of the company’s stock valued at $93,000 after purchasing an additional 5,399 shares during the last quarter. 91.19% of the stock is owned by institutional investors and hedge funds.
Oxford Immunotec Global Company Profile
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.
Further Reading: What are the components of an earnings report?
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.